If digestion is built to take proteins apart, why does BPC-157 appear in capsules when almost every other research peptide is supplied for injection?
It is a fair question, and the answer is more interesting than either of the two positions usually offered. The compound does have a specific structural argument behind it, published and mechanistic rather than marketing. The human evidence for the oral route, however, is far thinner than the volume of writing about it suggests. Both of those things are true at once, and this piece sets out where the line between them sits.
Everything below describes published laboratory and preclinical research. None of it is a claim about a product, a recommendation of use, or a statement about outcomes in people.
Why the gut is hostile to peptides
A peptide is a short chain of amino acids, and the digestive tract exists to reduce exactly that kind of chain to its parts. Stomach acid unfolds the molecule, and enzymes go to work on the exposed bonds. Pepsin, the stomach’s principal protease, cleaves preferentially beside particular residues, so a peptide with those residues exposed is cut apart before absorption.
This is the practical reason the injectable route dominates. It is not a delivery preference or a matter of convention. Insulin, the most familiar therapeutic peptide of all, has been injected for a century for the same reason. When a peptide is given by mouth, the default expectation is that very little of it will arrive intact.
That default is the backdrop against which any oral peptide claim has to be read.
The structural case for BPC-157
BPC-157 is a chain of fifteen amino acids, which makes it a pentadecapeptide. Two features of its origin and structure are what put the oral route on the table.
The first is where it came from. It was identified as a fragment of a protein found in human gastric juice, rather than designed at a bench and then tested for stability. A sequence that is already present in the stomach starts from a different position than one that is not. The same review reports that the peptide is “not destroyed in human gastric juice for more than 24 h”, which is an unusual property for a chain of that length.
The second is the mechanism, and this is where the recent literature has become more specific. A 2026 review in Pharmaceutics describes a polyproline cluster within the sequence that adopts a polyproline II helix, and associates that conformation with resistance to pepsin and to gastric proteolysis. That is a concrete structural explanation rather than an observation, and it is the strongest part of the case.
So the argument is not simply that BPC-157 seems to survive the stomach. There is a published account of why it might.
What has actually been tested in people
This is where the picture narrows sharply, and it is the part most writing on the subject moves past quickly.
A systematic review published in 2025 screened 544 records spanning 1993 to 2024. Thirty-six met the inclusion criteria. Of those, thirty-five were preclinical and one was clinical.
The review graded what it found as level IV and level V evidence, the lower tiers of the evidence hierarchy, and stated plainly that no clinical safety data were identified. That is not a criticism of the underlying laboratory work, which is extensive. It is a description of how little of it has moved into people.
The 2026 Pharmaceutics review reaches a similar place from a pharmaceutical-development angle. It reports that the available clinical evidence amounts to fewer than thirty subjects across three uncontrolled pilot studies, none of which used a standardised pharmaceutical preparation, and notes that no pharmaceutical-grade formulation has been developed or validated. Its conclusion is worth sitting with: the obstacle it identifies is not the biological activity but the absence of the basic pharmaceutical groundwork, meaning characterised formulations and validated pharmacokinetics.
There is one further detail that matters specifically for the oral question, and it is routinely lost in summaries. The best-known human work on this compound studied a formulation called PL 14736, developed by Pliva in Croatia, for ulcerative colitis. That formulation was an enema. The first-in-human safety and tolerability work gave it rectally to healthy volunteers (Veljača et al., Gut 2003;51:A309), and the phase II that followed used enemas in patients (Gastroenterology 2005;128:584). Both were reported as conference abstracts rather than full papers.
Rectal delivery places the compound against the gut wall and bypasses the stomach completely, so it tests something quite different from surviving digestion. The gastric-stability work and the human dosing work are pointing at two different routes, and neither one is a capsule.
The concentration problem
There is a second limitation, separate from volume, and it is one the research community itself has raised.
Reporting in early 2026 noted that of roughly two hundred BPC-157 studies, nearly all list the same Croatian research group among their authors, and quoted a separate review team warning that this concentration risks confirmation bias and makes the work harder to establish with the wider medical community. That reporting also recorded that a human trial registered in 2015 was withdrawn before external review and never formally published.
A large body of literature and a well-replicated finding are different things. Independent groups repeating a result in their own laboratories is what moves a compound from interesting to established, and that step has largely not happened here.
Regulatory position
For completeness, because it is part of the current picture: the US Food and Drug Administration lists BPC-157 among the bulk drug substances it considers may present significant safety risks, the category for which it does not permit compounding while its evaluation continues. It is not an approved medicine in that jurisdiction, and material supplied for laboratory research is supplied for that purpose only.
In summary
BPC-157 is the one peptide where the oral route has a genuine mechanistic argument behind it. It was found in gastric juice, it is reported to persist there for more than a day, and there is now a published structural explanation involving a polyproline II helix and resistance to pepsin. That is a real body of work and it deserves to be described accurately.
What does not yet exist is the human half. The oral dosing studies are preclinical. The human studies are few, uncontrolled, small, and the best documented of them delivered the compound rectally rather than by mouth. No pharmaceutical-grade oral formulation has been characterised, and the published record is dominated by a single group.
Three habits are worth carrying into any reading of this literature:
- Route is part of the result. A finding from an intragastric or rectal study does not automatically transfer to a capsule, and the two are frequently conflated in summaries.
- Preclinical volume is not clinical evidence. Thirty-five animal studies and one clinical study describe a compound at an early stage, however consistent the animal work looks.
- Ask who did the work. Replication by unrelated groups is the step that turns a promising signal into a settled one, and it is the step most often missing here.
For the wider question of how research-compound formats differ and why the format is chosen, see vials, click-dial pens and fixed-dose pens compared.